The current pricing of cancer treatments is unsustainable
World of DTC Marketing
NOVEMBER 24, 2021
From 2009 to 2019, the median monthly treatment costs for new drugs at launch reached $11,755 in the U.S… From 2009-10 to 2018-19, the lowest average monthly costs for new cancer drugs approved by the U.S. Rapamycin was approved in 1999 and it’s also worth noting their Phase II was a tiny patient population.
Let's personalize your content